CellMax Life announces genetic cancer risk test for 98 genes, 24 hereditary Cancers

New saliva test offers broadest gene panel


CellMax Life, the precision cancer testing company, announced the immediate availability in India of the CellMax-DNA Genetic Cancer Risk Test, which examines 98 genes across 24 hereditary cancers using its proprietary SMSEQ Platform. The CellMax-DNA Genetic Cancer Risk Test requires only a saliva sample.

CellMax Life's DNA test uses next generation sequencing to detect gene mutations known to increase lifetime cancer risk. The test surveys for increased risk of 24 cancers including some of the most common cancers: breast, lip, lung, colorectal and stomach, along with prostate, bladder, thyroid, ovary and others.

As an example of the extensive breadth of the gene panel analyzed by CellMax Life, to assess breast cancer risk, the CellMax-DNA test covers BRCA1 and BRCA2 genes entirely, and also examines a number of other genes associated with breast cancer, including ATM, BARD1, CDH1, CHEK2, NBN, NF1, PALB2, PPM1D, PTEN, RAD51C, RAD51D, STK11, TP53.

Genetic mutations can increase cancer risk by 20 times

Genetic mutations associated with increased cancer risk are passed from parent to offspring. These inherited abnormal genes are in contrast to acquired mutations which occur after birth and over time, and include environmental factors and lifestyle choices such as smoking or sun exposure.

Individuals with certain inherited genetic mutations carry a higher lifetime risk for various cancers. Their risk of getting these cancers can be up to 20 times greater than individuals without these mutations. Cancers impacted by these inherited gene mutations are typically referred to as hereditary cancers.

"The public has already been fairly well-educated on the value of genetic testing for breast cancer," said Dr. Ashish Nimgaonkar, MD, Asst. Professor of Medicine and Associate Medical Director, Center for Bioengineering Innovation and Design at Johns Hopkins University, USA. "The ability of the CellMax-DNA Genetic Cancer Risk Test to identify mutations associated with 24 hereditary cancers in an affordable saliva test, is valuable to both patients and their doctors in planning for appropriate screening frequency and preventative measures."
"Early cancer detection is the most effective way to fight cancer," said Dr. Tai Cheng-Jeng, MD, PhD, Chief, Division of Hematology & Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taiwan. "CellMax Life's convenient genetic cancer saliva DNA test based on the next generation sequencing SMSEQ platform offers the broadest gene panel for known hereditary cancers, allowing doctors and their patients to collaborate on personalized, optimal health planning."

Cancer risk identification enables personalized screening for more effective medicine

According to the U.S. National Cancer Institute, more than 4 in 10 people in the United States will get cancer in their lifetime. Individuals who inherit mutated genes associated with cancer:

- Have a greater risk of getting cancer
- Tend to get their cancers earlier in life
- The cancer is usually more aggressive

Thus, individuals who know they have inherited an increased cancer risk can work with their doctors to plan for earlier and more frequent cancer screening.

It is well-accepted that the prognosis for cancer survival is higher when detected at early stages. The survival outlook is assessed by the 5-year survival rate stratified based on stage of detection. Some examples are shown below.

- Colorectal cancer: Stage one has more than 90% survival rate, while stage three and four detection survival is as low as 10%.

- Breast cancer: Stage one has almost a 100% survival rate. Stage four cancer has only 22%.

The ability for doctors to tailor this screening to individuals with higher risk allows for more efficient and effective medicine.
"Our goal is to make personalized, comprehensive cancer diagnostics affordable and accessible to every individual," said Dr. Mana K Javey, MD, PhD, VP of Medical Affairs, CellMax Life. "By providing the industry's broadest gene panel for hereditary cancer risk testing, we are enabling individuals and their physicians to do high-impact health planning."

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email